Evercore ISI Group Downgrades Ultragenyx Pharmaceutical to In-Line, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 93.1%

Neg 93.1% Neu 0% Pos 0%

Evercore ISI Group analyst Liisa Bayko downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to In-Line and lowers the price target from $34 to $16.